A prognostic model to predict survival in 867 World Health Organization - Defined essential thrombocythemia at diagnosis: A study by the International Working Group on Myelofibrosis Research and Treatment

Blood

Volumn 120, Issue 6, 2012, Pages 1197-1201

  Passamonti, Francesco ^a   Thiele, Jürgen ^b   Girodon, Francois ^c   Rumi, Elisa ^d   Carobbio, Alessandra ^e   Gisslinger, Heinz ^f   Kvasnicka, Hans Michael ^g   Ruggeri, Marco ^h   Randi, Maria Luigia ⁱ   Gangat, Naseema ^j   Vannucchi, Alessandro Maria ^k   Gianatti, Andrea ^e   Gisslinger, Bettina ^f   Müllauer, Leonhard ^f   Rodeghiero, Francesco ^h   D'Amore, Emanuele S G ^h   Bertozzi, Irene ⁱ   Hanson, Curtis A ^j   Boveri, Emanuela ^d   Marino, Filippo ⁱ   Maffioli, Margherita ^a   Caramazza, Domenica ^a   Antonioli, Elisabetta ^k   Carrai, Valentina ^k   Buxhofer Ausch, Veronika ^f   Pascutto, Cristiana ^d   Cazzola, Mario ^d   Barbui, Tiziano ^e   Tefferi, Ayalew ^j   more..

^a OSPEDALE DI CIRCOLO   (Italy)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c HÔPITAL DU BOCAGE   (France)

^d UNIVERSITY OF PAVIA   (Italy)

^e OSPEDALI RIUNITI   (Italy)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g GOETHE UNIVERSITY   (Germany)

^h SAN BORTOLO HOSPITAL   (Italy)

ⁱ UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^j MAYO CLINIC   (United States)

^k UNIVERSITY OF FLORENCE   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC SCORE FOR ESSENTIAL THROMBOCYTHEMIA MODEL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PHENOTYPE; POLYCYTHEMIA VERA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SENESCENCE; SURVIVAL; THROMBOCYTHEMIA; THROMBOSIS; WORLD HEALTH ORGANIZATION;

EID: 84865187605     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-01-403279     Document Type: Article

References (27)

1. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092-1097. (Pubitemid 47281402)
2. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117(10):755-761. (Pubitemid 39482529)
3. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006;81(2):159-166. (Pubitemid 43205767)
4. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI,Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol. 1986;23(2):132-143.
5. Wilkins BS, Erber WN, Bareford D, et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood. 2008;111(1):60-70.
6. Thiele J, Kvasnicka HM, Mullauer L, Buxhofer-Ausch V, Gisslinger B, Gisslinger H. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood. 2011;117(21):5710-5718.
7. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29(23):3179-3184.
8. Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia. 2008;22(5):905-914. (Pubitemid 351698623)
9. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761-770.
10. Palandri F, Polverelli N, Catani L, Ottaviani E, Baccarani M, Vianelli N. Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study. Ann Hematol. 2011;90(8):933-938.
11. Girodon F, Dutrillaux F, Broseus J, et al. Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population-based study of 311 patients. Leukemia. 2010;24(4):900-903.
12. Gangat N, Wolanskyj AP, McClure RF, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia. 2007;21(2):270-276. (Pubitemid 46158119)
13. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22(2):437-438. (Pubitemid 351250553)
14. Kalbfleisch J. D., Prentice, R. L. The Statistical Analysis of Failure Time Data. New York, NY: Wiley; 1980.
15. Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117(22):5857-5859.
16. Girodon F, Bonicelli G, Schaeffer C, et al. Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study. Haematologica. 2009;94(6):865-869.
17. Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood. 2007;109(6):2310-2313. (Pubitemid 46425868)
18. Carobbio A, Finazzi G, Antonioli E, et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood. 2008;112(8):3135-3137.
19. Carobbio A, Antonioli E, Guglielmelli P, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol. 2008;26(16):2732-2736.
20. Caramazza D, Caracciolo C, Barone R, et al. Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms. Ann Hematol. 2009;88(10):967-971.
21. Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008;93(11):1645-1651.
22. Gangat N, Wolanskyj AP, Schwager SM, Hanson CA, Tefferi A. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera. Cancer. 2009;115(24):5740-5745.
23. Passamonti F, Rumi E, Pascutto C, Cazzola M, Lazzarino M. Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. J Thromb Haemost. 2009;7(9):1587-1589.
24. Dahabreh IJ, Zoi K, Giannouli S, Zoi C, Loukopoulos D, Voulgarelis M. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res. 2009;33(1):67-73.
25. Lussana F, Caberlon S, Pagani C, Kamphuisen PW, Buller HR, Cattaneo M. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb Res. 2009;124(4):409-417.
26. Passamonti F, Maffioli M, Caramazza D, Cazzola M. Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies. Oncotarget. 2011;2(6):485-490.
27. Caramazza D, Begna KH, Gangat N, et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia. 2011;25(1):82-88.